Waits, AlexanderAlexanderWaitsChen, Jau-YuanJau-YuanChenCheng, Wei-HongWei-HongChengYeh, Jih-IJih-IYehSZU-MIN HSIEHChen, CharlesCharlesChenJanssen, RobertRobertJanssenLien, Chia EnChia EnLienLin, Tzou-YienTzou-YienLin2022-10-282022-10-282022-08-291201-9712https://scholars.lib.ntu.edu.tw/handle/123456789/624133Older adults are subject to higher COVID-19 infection and mortality rates. Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated in phase 2 clinical trial for the general population, and negative correlations have been observed between immune responses and age, however, older adults were under-represented.enImmunogenicity; Immunosenescence; MVC-COV1901 vaccine; Older adults; SARS-Cov-2[SDGs]SDG3journal article10.1016/j.ijid.2022.08.021360497002-s2.0-85138791117WOS:000863702000004https://api.elsevier.com/content/abstract/scopus_id/85138791117